Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance upgrade on Thursday 4th of May 2017 from 8.00am to 9.00am (BST).

During this time our websites will be offline temporarily. If you have any questions please use the feedback button on this page. We apologise for any inconvenience this might cause and thank you for your patience.


Issue 17, 2004
Previous Article Next Article

Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?

Author affiliations

Abstract

The evolution of crystal engineering into a form of supramolecular synthesis is discussed in the context of problems and opportunities in the pharmaceutical industry. Specifically, it has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals, can be rationally designed using crystal engineering, and the strategy affords new intellectual property and enhanced properties for pharmaceutical substances.

Graphical abstract: Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?

Back to tab navigation
Please wait while Download options loads

Publication details

The article was received on 11 Feb 2004, accepted on 26 May 2004 and first published on 05 Aug 2004


Article type: Feature Article
DOI: 10.1039/B402150A
Citation: Chem. Commun., 2004, 1889-1896
  •   Request permissions

    Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?

    Ö. Almarsson and M. J. Zaworotko, Chem. Commun., 2004, 1889
    DOI: 10.1039/B402150A

Search articles by author